NDC product
RECOMBIVAX HB
NDC 0006-4981 · Merck Sharp & Dohme LLC
Key facts
| Product NDC | 0006-4981 |
|---|---|
| Proprietary name | RECOMBIVAX HB |
| Nonproprietary name | Hepatitis B Vaccine (Recombinant) |
| Substances | HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN |
| Dosage form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR, SUBCUTANEOUS |
| Labeler | Merck Sharp & Dohme LLC |
| Product type | VACCINE |
| Marketing category | BLA |
| Application number | BLA101066 |
| Pharmacologic classes | Actively Acquired Immunity [PE], Hepatitis B Vaccines [CS], Inactivated Hepatitis B Virus Vaccine [EPC], Vaccines, Inactivated [CS] |
| Marketing start | Jul 23, 1986 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: